328 related articles for article (PubMed ID: 28539614)
1. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.
López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Rodríguez-Mora S; Coiras M; Alcamí J; Moreno S
Sci Rep; 2017 May; 7(1):2385. PubMed ID: 28539614
[TBL] [Abstract][Full Text] [Related]
2. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
3. Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and
Vicenti I; Dragoni F; Monti M; Trombetta CM; Giannini A; Boccuto A; Saladini F; Rossetti B; De Luca A; Ciabattini A; Pastore G; Medaglini D; Orofino G; Montomoli E; Zazzi M
J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33048041
[TBL] [Abstract][Full Text] [Related]
4. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
[TBL] [Abstract][Full Text] [Related]
5. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
[TBL] [Abstract][Full Text] [Related]
6. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
[TBL] [Abstract][Full Text] [Related]
7. Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.
Nakata H; Maeda K; Das D; Chang SB; Matsuda K; Rao KV; Harada S; Yoshimura K; Ghosh AK; Mitsuya H
Sci Rep; 2019 Mar; 9(1):4828. PubMed ID: 30886166
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal.
Martínez-Bonet M; Clemente MI; Álvarez S; Díaz L; García-Alonso D; Muñoz E; Moreno S; Muñoz-Fernández MÁ
Antiviral Res; 2015 Nov; 123():163-71. PubMed ID: 26427554
[TBL] [Abstract][Full Text] [Related]
9. HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB.
Saleh S; Lu HK; Evans V; Harisson D; Zhou J; Jaworowski A; Sallmann G; Cheong KY; Mota TM; Tennakoon S; Angelovich TA; Anderson J; Harman A; Cunningham A; Gray L; Churchill M; Mak J; Drummer H; Vatakis DN; Lewin SR; Cameron PU
Retrovirology; 2016 Jul; 13(1):49. PubMed ID: 27459960
[TBL] [Abstract][Full Text] [Related]
10. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
[TBL] [Abstract][Full Text] [Related]
11. Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.
López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Vivancos MJ; Luna L; Moreno S
Biochem Pharmacol; 2020 Dec; 182():114231. PubMed ID: 32979351
[TBL] [Abstract][Full Text] [Related]
12. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.
Pérez M; de Vinuesa AG; Sanchez-Duffhues G; Marquez N; Bellido ML; Muñoz-Fernandez MA; Moreno S; Castor TP; Calzado MA; Muñoz E
Curr HIV Res; 2010 Sep; 8(6):418-29. PubMed ID: 20636281
[TBL] [Abstract][Full Text] [Related]
13. Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism.
Díaz L; Martínez-Bonet M; Sánchez J; Fernández-Pineda A; Jiménez JL; Muñoz E; Moreno S; Álvarez S; Muñoz-Fernández MÁ
Sci Rep; 2015 Jul; 5():12442. PubMed ID: 26199173
[TBL] [Abstract][Full Text] [Related]
14. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
Marsden MD; Wu X; Navab SM; Loy BA; Schrier AJ; DeChristopher BA; Shimizu AJ; Hardman CT; Ho S; Ramirez CM; Wender PA; Zack JA
Virology; 2018 Jul; 520():83-93. PubMed ID: 29800728
[TBL] [Abstract][Full Text] [Related]
15. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
[TBL] [Abstract][Full Text] [Related]
16. A CCR5
Terahara K; Iwabuchi R; Hosokawa M; Nishikawa Y; Takeyama H; Takahashi Y; Tsunetsugu-Yokota Y
BMC Res Notes; 2019 Apr; 12(1):242. PubMed ID: 31036079
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
[TBL] [Abstract][Full Text] [Related]
18. Maraviroc: a review of its use in HIV infection and beyond.
Woollard SM; Kanmogne GD
Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256
[TBL] [Abstract][Full Text] [Related]
19. Selective BCL-X
Ren Y; Huang SH; Macedo AB; Ward AR; Alberto WDC; Klevorn T; Leyre L; Copertino DC; Mota TM; Chan D; Truong R; Rohwetter T; Zumbo P; Dündar F; Betel D; Kovacs C; Benko E; Bosque A; Jones RB
J Virol; 2021 Jul; 95(15):e0242520. PubMed ID: 33980597
[TBL] [Abstract][Full Text] [Related]
20. Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In Vitro.
Anderson JL; Mota TM; Evans VA; Kumar N; Rezaei SD; Cheong K; Solomon A; Wightman F; Cameron PU; Lewin SR
PLoS One; 2016; 11(7):e0158778. PubMed ID: 27383184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
